Background Outcomes of coronavirus disease 2019 (COVID‐19) in patients with neuromyelitis optica spectrum disorders (NMOSD) or myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), often treated with immunosuppressive therapies, are still unknown. Methods We conducted a multicenter, retrospective, observational cohort study among all French expert centers for neuromyelitis optica and related disorders. Patients with NMOSD or MOGAD included in the study received a confirmed or highly suspected diagnosis of COVID‐19 between 1 March 2020 and 30 June 2020. Main outcome was COVID‐19 severity score assessed on a seven‐point ordinal scale ranging from 1 (not hospitalized with no limitations on activities) to 7 (death). Results Fifteen cases (mean SD age: 39.3 14.3 years, 11 female) were included. Five patients (33.3%) were hospitalized, all receiving rituximab. A 24‐year‐old patient with positive aquaporine‐4 antibody, with obesity as comorbidity, needed mechanical ventilation. Outpatients were receiving anti‐CD20 (5), mycophenolate mofetil (3) or azathioprine (3). They were younger (mean SD age: 37.0 13.4 years), with a longer disease duration (mean SD: 8.3 6.3 years) and had a lower expanded disability severity score (EDSS) score (median range EDSS: 2.5 0–4) relative to patients requiring hospitalization (mean SD age: 44.0 16.4 years, mean SD disease duration: 5.8 5.5 years, median range EDSS: 4 0–6.5). Conclusions COVID‐19 outcome was overall favorable in this cohort. Larger international studies are needed to identify risk factors of severe COVID‐19; however, we recommend personal protective measures to reduce risk of SARS‐CoV‐2 infection in this immunocompromised population. We present a cohort of 15 patients with neuromyelitis optica and associated disorders who had Coronavirus disease 2019 (COVID‐19). COVID‐19 outcome was overall favorable, 5 patients, all on Rituximab, needed hospitalization, and one patient needed mechanical ventilation.